Moleculin Biotech (MBRX) Profit After Tax Growth (3y) (2019 - 2026)
Moleculin Biotech (MBRX) Profit After Tax Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.02% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 17.25% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.89% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.44% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -29.12% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 59.34% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.57% |
| Dec 31, 2025 | 62.58% |
| Sep 30, 2025 | -43.32% |
| Jun 30, 2025 | -38.00% |
| Mar 31, 2025 | 4.91% |
| Dec 31, 2024 | -32.89% |
| Sep 30, 2024 | -16.84% |
| Jun 30, 2024 | -12.33% |
| Mar 31, 2024 | -13.07% |
| Dec 31, 2023 | -57.97% |
| Sep 30, 2023 | -18.22% |
| Jun 30, 2023 | 16.08% |
| Mar 31, 2023 | -87.07% |
| Dec 31, 2022 | -21.48% |
| Sep 30, 2022 | -27.66% |
| Jun 30, 2022 | -77.05% |
| Mar 31, 2022 | -19.33% |
| Dec 31, 2021 | -0.23% |
| Sep 30, 2021 | -29.20% |
| Jun 30, 2021 | 6.09% |